Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
paper
Cited
Public
Unavailable
- Authors
- Gelernter, Joel; Gueorguieva, Ralitza; Kranzler, Henry R; Zhang, Huiping; Cramer, Joyce; Rosenheck, Robert; Krystal, John H; VA Cooperative Study #425 Study Group
- Year
- 2007
- Journal
- Alcoholism, clinical and experimental research
- PMID
- 17374034
- DOI
- 10.1111/j.1530-0277.2007.00339.x
BACKGROUND: Pharmacotherapy of alcohol dependence (AD) is at an early stage of development; currently available medications have limited efficacy. It would be clinically valuable to identify, before initiation of a course of treatment, those patients who, based on genetic markers, are most likely to respond to a specific pharmacotherapy. A previous report suggested that a functional variant at the genetic locus encoding the mu opioid receptor (Asn40Asp) is such a marker, in short-term (3-month) treatment with the opioid-blocking drug naltrexone (NTX). METHODS: We studied polymorphic variants at each of the 3 opioid receptor genes--OPRM1, OPRD1, and OPRK1, which encode the mu, delta, and kappa opioid receptors, respectively--including the OPRM1 Asn40Asp variant--as predictors of response to NTX or placebo in 215 alcohol-dependent male subjects who participated in Veterans Affairs Cooperative Study 425, "Naltrexone in the Treatment of Alcohol Dependence." RESULTS: At the 3-month time point, treatment condition, age, and the pretreatment number of drinks per drinking day were all significant (p<0.05) predictors of the rate of relapse and time to relapse. Although NTX had no significant effect on relapse to heavy drinking in the overall sample in CSP 425, it significantly reduced relapse in the subgroup that provided DNA for analysis (i.e., the present study sample). There were no significant interactions between any individual single nucleotide polymorphisms studied and NTX treatment response. CONCLUSIONS: These results do not support association of the OPRM1 Asn40Asp polymorphism with NTX treatment response for AD.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder. | Counts C et al. | β | 2025 | β |
| Explaining increased efficacy of naltrexone in the treatment of alcohol dependent patients with a family history of alcohol use disorder: A systematic review on the role of reward sensitivity and sweet liking. | van Amsterdam J et al. | β | 2025 | β |
| Introduction: Approved treatments for alcohol use disorder by regulatory agencies. | Camarini R et al. | β | 2024 | β |
| Alcohol use disorder conceptualizations and diagnoses reflect their sociopolitical context. | Boness CL et al. | β | 2023 | β |
| Association of <i>OPRK1</i> rs963549 and rs997917 polymorphisms with opioid use disorder and related phenotypes. | Γzkan-KotiloΔlu S et al. | β | 2023 | β |
| Effect of PDYN and OPRK1 polymorphisms on the risk of alcohol use disorder and the intensity of depressive symptoms. | Γzkan-KotiloΔlu S et al. | β | 2023 | β |
| Medications for treating alcohol use disorder: A narrative review. | Kranzler HR et al. | β | 2023 | β |
| OPRD1 rs569356 polymorphism has an effect on plasma norbuprenorphine levels and dose/kg-normalized norbuprenorphine values in individuals with opioid use disorder. | Kaya-AkyΓΌzlΓΌ D et al. | β | 2023 | β |
| Pharmacogenetics of Addiction Therapy. | Graham DP et al. | β | 2022 | β |
| Smoking As an Outcome Moderator In the Treatment of Alcohol Use Disorders. | van Amsterdam J et al. | β | 2022 | β |
| Developmental Considerations for the Use of Naltrexone in Children and Adolescents. | Stancil SL et al. | β | 2021 | β |
| FMRI-based prediction of naltrexone response in alcohol use disorder: a replication study. | Bach P et al. | β | 2021 | β |
| An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence. | Lin Y et al. | β | 2020 | β |
| Differential sensitivity of human neurons carrying ΞΌ opioid receptor (MOR) N40D variants in response to ethanol. | Scarnati MS et al. | β | 2020 | β |
| Genetic polymorphisms in the opioid receptor delta 1 (OPRD1) gene are associated with methadone dose in methadone maintenance treatment for heroin dependence. | Fang CP et al. | β | 2020 | β |
| On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications. | Nieto SJ et al. | β | 2020 | β |
| OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial. | Hendershot CS et al. | β | 2020 | β |
| Pharmacotherapies and personalized medicine for alcohol use disorder: a review. | Lohoff FW | β | 2020 | β |
| Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. | Hartwell EE et al. | β | 2020 | β |
| Alcohol use disorder relapse factors: A systematic review. | Sliedrecht W et al. | β | 2019 | β |
| Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial. | Roche DJO et al. | β | 2019 | β |
| Medication-enhanced behavior therapy for alcohol use disorder: Naltrexone, Alcoholics Anonymous Facilitation, and OPRM1 genetic variation. | Stewart SH et al. | β | 2019 | β |
| Pharmacogenetics of alcohol addiction: current perspectives. | Zastrozhin MS et al. | β | 2019 | β |
| Pharmacogenetics of alcohol use disorder treatments: an update. | Hartwell EE et al. | β | 2019 | β |
| A Critical Review of Methods and Results in the Search for Genetic Contributors to Alcohol Sensitivity. | Schuckit MA | β | 2018 | β |
| Delta Opioid Pharmacology in Relation to Alcohol Behaviors. | Alongkronrusmee D et al. | β | 2018 | β |
| Increased ethanol drinking in "humanized" mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms. | Henderson-Redmond AN et al. | β | 2018 | β |
| The frequency of <i>DRD2</i> rs1076560 and <i>OPRM1</i> rs1799971 in substance use disorder patients from the United Arab Emirates. | Alblooshi H et al. | β | 2018 | β |
| Association of OPRD1 Gene Variants with Opioid Dependence in Addicted Male Individuals Undergoing Methadone Treatment in the North of Iran. | Sharafshah A et al. | β | 2017 | β |
| Cebranopadol: novel dual opioid/NOP receptor agonist analgesic. | Raffa RB et al. | β | 2017 | β |
| Convergent Balancing Selection on the Mu-Opioid Receptor in Primates. | Sweeney CG et al. | β | 2017 | β |
| Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. | Smith AH et al. | β | 2017 | β |
| Observational study to calculate addictive risk to opioids: a validation study of a predictive algorithm to evaluate opioid use disorder. | Brenton A et al. | β | 2017 | β |
| Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. | Schacht JP et al. | β | 2017 | β |
| Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models. | Rinker JA et al. | β | 2017 | β |
| Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity. | Cservenka A et al. | β | 2017 | β |
| Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol. | Anderson RI et al. | β | 2017 | β |
| Alcohol addiction and the mu-opioid receptor. | Berrettini W | β | 2016 | β |
| Experimental psychopathology paradigms for alcohol use disorders: Applications for translational research. | Bujarski S et al. | β | 2016 | β |
| From genetic studies to precision medicine in alcohol dependence. | Sun Y et al. | β | 2016 | β |
| Opioid Antagonists and the A118G Polymorphism in the ΞΌ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype. | Ziauddeen H et al. | β | 2016 | β |
| Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction. | Berrettini W | β | 2016 | β |
| Pharmacogenomics in Psychiatric Practice. | El-Mallakh RS et al. | β | 2016 | β |
| Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms. | Jones JD et al. | β | 2016 | β |
| Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. | Soyka M et al. | β | 2016 | β |
| Adding Genetic Testing to Evidence-Based Guidelines to Determine the Safest and Most Effective Chronic Pain Treatment for Injured Workers. | Meshkin B et al. | β | 2015 | β |
| Advances in Medications and Tailoring Treatment for Alcohol Use Disorder. | Seneviratne C et al. | β | 2015 | β |
| A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice. | Bilbao A et al. | β | 2015 | β |
| Gene-gene interaction of ΞΌ-opioid receptor and GluR5 kainate receptor subunit is associated with smoking behavior in a Greek population: presence of a dose allele effect. | Misailidis G et al. | β | 2015 | β |
| OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients. | Foulds JA et al. | β | 2015 | β |
| Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders. | Helton SG et al. | β | 2015 | β |
| Pharmacotherapy for alcohol dependence: A stratified approach. | Thompson A et al. | β | 2015 | β |
| Subjective response as a consideration in the pharmacogenetics of alcoholism treatment. | Roche DJ et al. | β | 2015 | β |
| The pharmacogenetics of alcohol use disorder. | Jones JD et al. | β | 2015 | β |
| The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review. | Bauer IE et al. | β | 2015 | β |
| A brief history of research on the genetics of alcohol and other drug use disorders. | Schuckit MA | β | 2014 | β |
| Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. | Garbutt JC et al. | β | 2014 | β |
| Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis. | Jonas DE et al. | β | 2014 | β |
| Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol. | Ray LA et al. | β | 2014 | β |
| Nalmefene for the treatment of alcohol dependence: a current update. | Soyka M | β | 2014 | β |
| Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds. | Hendershot CS | β | 2014 | β |
| Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. | Arias AJ et al. | β | 2014 | β |
| Pharmacogenetics of OPRM1. | Crist RC et al. | β | 2014 | β |
| Pharmacological approaches to reducing craving in patients with alcohol use disorders. | Haass-Koffler CL et al. | β | 2014 | β |
| Pharmacologic treatment of alcoholism. | Anton RF et al. | β | 2014 | β |
| A cross-sectional study of attitudes about the use of genetic testing for clinical care among patients with an alcohol use disorder. | Strobel B et al. | β | 2013 | β |
| A variant on the kappa opioid receptor gene (OPRK1) is associated with stress response and related drug craving, limbic brain activation and cocaine relapse risk. | Xu K et al. | β | 2013 | β |
| Case-control association analysis of polymorphisms in the Ξ΄-opioid receptor, OPRD1, with cocaine and opioid addicted populations. | Crist RC et al. | β | 2013 | β |
| Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. | Schacht JP et al. | β | 2013 | β |
| NCK2 is significantly associated with opiates addiction in African-origin men. | Liu Z et al. | β | 2013 | β |
| Opioid pharmacogenetics of alcohol addiction. | Berrettini W | β | 2013 | β |
| Peter Riederer "70th birthday" neurobiological foundations of modern addiction treatment. | Jacob C | β | 2013 | β |
| Subjective response to alcohol among alcohol-dependent individuals: effects of the ΞΌ-opioid receptor (OPRM1) gene and alcoholism severity. | Ray LA et al. | β | 2013 | β |
| The ΞΌ-opioid receptor and treatment response to naltrexone. | Thorsell A | β | 2013 | β |
| Variation in Mu-Opioid Receptor Gene <i>(OPRM1)</i> as a Moderator of Naltrexone Treatment to Reduce Heavy Drinking in a High Functioning Cohort. | Chen AC et al. | β | 2013 | β |
| Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. | Kranzler HR et al. | β | 2013 | β |
| Association of Β΅-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. | Chamorro AJ et al. | β | 2012 | β |
| Current progress in pharmacologic treatment strategies for alcohol dependence. | Clapp P | β | 2012 | β |
| Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. | Ashenhurst JR et al. | β | 2012 | β |
| Epistatic effects between variants of kappa-opioid receptor gene and A118G of mu-opioid receptor gene increase susceptibility to addiction in Indian population. | Kumar D et al. | β | 2012 | β |
| Gender-stratified gene and gene-treatment interactions in smoking cessation. | Lee W et al. | β | 2012 | β |
| Hypermethylation of OPRM1 promoter region in European Americans with alcohol dependence. | Zhang H et al. | β | 2012 | β |
| Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. | Setiawan E et al. | β | 2012 | β |
| Large scale association analysis for drug addiction: results from SNP to gene. | Guo X et al. | β | 2012 | β |
| Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. | Anton RF et al. | β | 2012 | β |
| Neurobiology of consummatory behavior: mechanisms underlying overeating and drug use. | Barson JR et al. | β | 2012 | β |
| Pathological Gambling: Neuropsychopharmacology and Treatment. | Bullock SA et al. | β | 2012 | β |
| Personalized treatment of alcohol dependence. | Kranzler HR et al. | β | 2012 | β |
| Pharmacogenetically driven treatments for alcoholism: are we there yet? | Arias AJ et al. | β | 2012 | β |
| Pharmacogenetics of alcoholism: a clinical neuroscience perspective. | Ray LA et al. | β | 2012 | β |
| Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study. | Ray LA et al. | β | 2012 | β |
| Possible association between OPRM1 genetic variance at the 118 locus and alcohol dependence in a large treatment sample: relationship to alcohol dependence symptoms. | Koller G et al. | β | 2012 | β |
| The genetics of the opioid system and specific drug addictions. | Levran O et al. | β | 2012 | β |
| The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. | Ray LA et al. | β | 2012 | β |
| Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study. | Bujarski S et al. | β | 2012 | β |
| 5-HTTLPR as a potential moderator of the effects of adverse childhood experiences on risk of antisocial personality disorder. | Douglas K et al. | β | 2011 | β |
| A genetic determinant of the striatal dopamine response to alcohol in men. | Ramchandani VA et al. | β | 2011 | β |
| An overview of the genetic susceptibility to alcoholism. | Buscemi L et al. | β | 2011 | β |
| Genetics of alcohol dependence. | Kimura M et al. | β | 2011 | β |
| Opioid modulators for alcohol dependence. | Hillemacher T et al. | β | 2011 | β |
| OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. | Coller JK et al. | β | 2011 | β |
| Personalized addiction treatment: how close are we? | Oslin D | β | 2011 | β |
| Pharmacogenetic approaches to the treatment of alcohol addiction. | Heilig M et al. | β | 2011 | β |
| Pharmacogenetics of alcohol, nicotine and drug addiction treatments. | Sturgess JE et al. | β | 2011 | β |
| Pharmacogenomics of the human Β΅-opioid receptor. | Kasai S et al. | β | 2011 | β |
| The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. | Setiawan E et al. | β | 2011 | β |
| A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. | Vallender EJ et al. | β | 2010 | β |
| Consilient research approaches in studying gene x environment interactions in alcohol research. | Sher KJ et al. | β | 2010 | β |
| Emerging drugs to treat alcoholism. | Soyka M et al. | β | 2010 | β |
| Initial evidence of an association between OPRM1 and adolescent alcohol misuse. | Miranda R et al. | β | 2010 | β |
| Medication treatment of different types of alcoholism. | Johnson BA | β | 2010 | β |
| Nalmefene for treatment of alcohol dependence. | Soyka M et al. | β | 2010 | β |
| Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation. | Ray LA et al. | β | 2010 | β |
| Opioid antagonists for alcohol dependence. | RΓΆsner S et al. | β | 2010 | β |
| OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. | Mague SD et al. | β | 2010 | β |
| Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. | Mroziewicz M et al. | β | 2010 | β |
| Pharmacogenetics of alcohol and alcohol dependence treatment. | Kranzler HR et al. | β | 2010 | β |
| Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism. | Ray LA et al. | β | 2010 | β |
| Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. | Barr CS et al. | β | 2010 | β |
| The role of microRNAs in drug addiction: a big lesson from tiny molecules. | Pietrzykowski AZ | β | 2010 | β |
| Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. | Heilig M et al. | β | 2010 | β |
| Alcohol-use disorders. | Schuckit MA | β | 2009 | β |
| A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. | Kim SG et al. | β | 2009 | β |
| Effects of alcoholism typology on response to naltrexone in the COMBINE study. | Bogenschutz MP et al. | β | 2009 | β |
| Ethical considerations for administering alcohol or alcohol cues to treatment-seeking alcoholics in a research setting: can the benefits to society outweigh the risks to the individual? A commentary in the context of the National Advisory Council on Alcohol Abuse and Alcoholism -- Recommended Council Guidelines on Ethyl Alcohol Administration in Human Experimentation (2005). | Enoch MA et al. | β | 2009 | β |
| Genetics of alcohol dependence. | Gelernter J et al. | β | 2009 | β |
| Nicotine withdrawal sensitivity, linkage to chr6q26, and association of OPRM1 SNPs in the SMOking in FAMilies (SMOFAM) sample. | Hardin J et al. | β | 2009 | β |
| Now or Later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. | Boettiger CA et al. | β | 2009 | β |
| OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. | Oroszi G et al. | β | 2009 | β |
| Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. | Ooteman W et al. | β | 2009 | β |
| Relatively strong automatic appetitive action-tendencies in male carriers of the OPRM1 G-allele. | Wiers RW et al. | β | 2009 | β |
| Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence. | Garbutt JC et al. | β | 2009 | β |
| An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. | Anton RF et al. | β | 2008 | β |
| Approach to the genetics of alcoholism: a review based on pathophysiology. | KΓΆhnke MD | β | 2008 | β |
| Association between single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) and self-reported responses to alcohol in American Indians. | Ehlers CL et al. | β | 2008 | β |
| Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. | Filbey FM et al. | β | 2008 | β |
| Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. | Arias AJ et al. | β | 2008 | β |
| Endogenous opiates and behavior: 2007. | Bodnar RJ | β | 2008 | β |
| Genetic approaches to addiction: genes and alcohol. | Ducci F et al. | β | 2008 | β |
| Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. | Anton RF | β | 2008 | β |
| Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. | Tidey JW et al. | β | 2008 | β |
| Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. | O'Malley SS et al. | β | 2008 | β |
| Naltrexone in the treatment of alcohol dependence. | Unterwald EM | β | 2008 | β |
| Practitioner review: adolescent alcohol use disorders: assessment and treatment issues. | Perepletchikova F et al. | β | 2008 | β |
| Preserved DNA from past clinical trials yields new information about a subtype of alcoholism. | O'Brien CP | β | 2008 | β |
| Review. Evidence-based treatments of addiction. | O'Brien CP | β | 2008 | β |
| Review. Neurogenetic studies of alcohol addiction. | Crabbe JC | β | 2008 | β |
| Role of pharmacogenetics in variable response to drugs: focus on opioids. | Kadiev E et al. | β | 2008 | β |
| Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. | Krishnan-Sarin S et al. | β | 2008 | β |
| Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. | Johnson BA | β | 2008 | β |
| Pharmacogenetic aspects of addictive behaviors. | Hejazi NS | β | 2007 | β |
| Polymorphisms in the mu-opioid receptor gene (OPRM1) and the implications for alcohol dependence in humans. | van der Zwaluw CS et al. | β | 2007 | β |
| Toward a rational selection of treatment for addiction. | O'Brien CP | β | 2007 | β |
| Treatment of addiction in the era of genomic medicine. | O'Brien C | β | 2007 | β |